There is enough cash for 3 quarters , see below , a good battery deal would give a nice lift to the share price , we have extra strong leadership in place with our CEO and board , I bet the blow torch is fired up on the battery division to do a decent deal and some up front cash or grant .
The Company anticipates receiving a larger R&D tax incentive than in prior years, estimated to be greater than $3m, during the quarter ending 31 December 2022. The Company remains diligent in managing future cash requirements and considers the need for further funding on a continuing basis. AnteoTech had $6.4 million cash on hand as at 30 September 2022 and no debt.
Discontinuation of the trial enables a reallocation of staff resources and cash in the order of $700,000 to be allocated to the acceleration of future POC diagnostic tests under consideration by AnteoTech’s New Product Council.
Ann: European RAT Clinical Trial Halted to Refocus Initiatives, page-145
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
-0.002(8.33%) |
Mkt cap ! $54.31M | |||
| Open | High | Low | Value | Volume |
| 2.4¢ | 2.4¢ | 2.2¢ | $12.59K | 542.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 487271 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.3¢ | 200000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| ADO (ASX) Chart |